The first patient has been dosed in a Phase 1 clinical study testing AMX0114, an experimental therapy being developed by…
Michela Luciano, PhD
Michela Luciano is a Science Writer at BioNews. Originally from the picturesque mountain town of L’Aquila, Italy, Michela holds a PhD in Molecular Biology from the University of Salzburg. Her research focused on the role of inflammation in acute myeloid leukemia. With a deep passion for scientific communication, Michela transitioned into her first role as Scientific Writer in 2022. Outside of work she enjoys street photography, mountain hikes, running, and spending as much time as possible outdoors.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Michela Luciano, PhD
The first patient has been enrolled in an expanded access program (EAP) trial evaluating MN-166 (ibudilast), Medicinova’s oral anti-inflammatory…
Denali Therapeutics‘ oral candidate DNL343 has failed to reduce levels of an established biomarker of nerve cell damage in…
Pathmaker Neurosystems has received three new patents — two in the U.S. and one in Japan — that cover…
Tiziana Life Sciences is seeking regulatory clearance in the U.S. to launch a Phase 2 clinical trial evaluating foralumab…
Woolsey Pharmaceuticals has extended its Series B preferred financing round, securing additional funds to continue advancing its ROCK inhibitor…